PD-L1

[Molecular Carcinogenesis] Scientists hypothesized that TGF-β receptor inhibition may alter Pancreatic ductal adenocarcinoma progression and antitumor immunity in the tumor microenvironment.

[Nature Communications] By investigating the resistance mechanisms, scientists found that MCL1 and JUNB modulated the mitochondrial apoptosis pathway. JUNB encoded a transcription factor that downregulates FasL and TRAIL receptors, upregulated the MCL1 relative BCL2A1, and activated the NF-κB pathway.

[Nature Cancer] Researchers showed that immune-checkpoint blockade (ICB) therapy selects for ligand-dependent corepressor (LCOR)low CSCs with reduced antigen processing/presentation machinery driving immune escape and ICB resistance in triple-negative breast cancer.

[Immunity] Although PD-1 and TIGIT are thought to regulate different costimulatory receptors, effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226.

[Journal of Hepatology] Scientists identified a proinflammatory hepatocyte subpopulation that developed primarily from periportal hepatocytes and to a lesser extent from pericentral hepatocytes and played key immunoregulatory roles in endotoxemia.

[Cancer Discovery] Scientists described the identification and characterization of INCB086550, a novel, oral, small-molecule PD-L1 inhibitor.